Dagaint	بمغمام	04/40/0006	
<u>uecaibt</u>	uate:	01/19/2006	_

Docket No.:

10520572 - GAU: 1626 Serial No.: 10/520,572

RLL-256.1CIPUS

INFORMATION DISCLOSURE CITATION

Applicants: MEHTA et al.

Filed: 1/7/2005

Group:

Rec'd PCT/PTO 19 JAN ZUUS

		- -	U.J. F.	ATENT DOCUMENTS	1		
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	2,490,714	12/6/1949	Searle	260	239	
	A2	3,176,019	3/30/1965	Campbell et al.	260	293.4	
•	A3	5,001,160	3/19/1991	McPherson et al.	514	255	
	A4	5,164,402	11/17/1992	Brighty	514	300	·
	A5	5,281,601	1/25/1994	Cross et al.	514	320	
	A6	5,397,800	3/14/1995	Alker et al.	514	413	
	A7	5,948,792	9/7/1999	Tsuchiya et al.	514	317	
	A8	6,130,232	10/10/2000	Mase et al.	514	318	
	A 9	6,174,900	1/16/2001	Okada et al.	514	317	
	A10	6,313,312	11/6/2001	Banks <i>et al.</i>	548	452	
	ļ. <u>.</u>						
			FOREIGN	PATENT DOCUMENTS			
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	B1	CA 2155320	8/19/1993	Canada	C07D	211/68	
.= .=.	B2	EP 0 325 571	7/26/1989	EPO	C07C	215/54	
	В3	EP 0 388 054	9/19/1990	EPO	C07D	207/08	
	B4	EP 0 413 455	2/20/1991	EPO	C07D	401/04	
	B5	EP 0 613 232	8/31/1994	EPO	H02M	3/335	
	B6	EP 0 801 067	10/15/1997	EPO	C07D	453/02	
	B7	EP 0 823 423	2/11/1998	EPO	C07D	211/46	
	B8	EP 0 863 141	9/9/1998	EPO	C07D	401/06	
	В9	GB 940,540	10/30/1963	UK	C07C		<u> </u>

EXAMINER	/Susannah	Chung/	(07/29/2008)
----------	-----------	--------	--------------

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Recei̇̀pt date: -01/19/2006		.10520572 - GAU: 162
receipt date. 01/19/2000		110020012 - GMO. 102
·	Docket No.:	Serial No.: 10/520,572

INFORMATION DISCLOSURE CITATION

RLL-256.1CIPUS

Applicants: MEHTA et al.

Filed: 1/7/2005 Group:

Г		1			
B10	JP 135958/1994	5/17/1994	Japan	C07D	333/16
B11	JP 92921/1994	4/5/1994	Japan	C07C	237/20
B12	WO 91/09013	6/27/1991	PCT	C07D	207/08
B13	WO 93/16018	8/19/1993	PCT	C05F	17/02
B14	WO 93/16048	8/19/1993	PCT	C07D	211/26
B15	WO 96/33973	10/31/1996	PCT `	C07D	211/46
B16	WO 97/45414	12/4/1997	PCT	C07D	211/58
B17	WO 98/05641	2/12/1998	PCT	C07D	211/46
B18	WO 98/29402	7/9/1998	PCT	C07D	311/20
B19	WO 98/53814	12/3/1998	PCT	A61K	31/395
B20	WO 01/42212	6/14/2001	PCT	C07D	211/48
B21	WO 01/42213	6/14/2001	PCT	C07D	211/58
B22	WO 01/90081	11/29/2001	PCT	C07D	241/08
B23	WO 02/00652	1/3/2002	PCT	C07D	453/02
B24	WO 02/04402	1/17/2002	PCT	C07C	219/10
B25	WO 02/51841	7/4/2002	PCT	C07D	453/02
B26	WO 02/06241	1/24/2002	PCT	C07D	223/16
B27	WO 02/53564	7/11/2002	PCT	C07D	453/02
B28	WO 04/004629	1/15/2004	PCT	A61K	
B29	WO 04/005252	1/15/2004	PCT	C07D	209/52
B30	WO 04/014363	2/19/2004	PCT	A61K	31/40
B31	WO 04/014853	2/19/2004	PCT	C07D	209/02
B32	WO 04/018422	3/4/2004	PCT	C07D	209/52
B33	WO 04/052857	6/24/2004	PCT	C07D	209/52
B34	WO 04/056767	7/8/2004	PCT	C07D	207/14
B35	WO 04/056810	7/8/2004	PCT	C07D	405/12
B36	WO 04/056811	7/8/2004	PCT	C07D	405/12

EXAMINER /Susannah Chung/ (07/29/2008) **DATE CONSIDERED**

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Receipt date: 01/19/2006	Docket No.: 10520572 - GAU Serial No.: 10/520, RLL-256.1CIPUS		
INFORMATION DISCLOSURE CITATION	Applicants: MEHTA et al.		
	Filed: 1/7/2005	Group:	

8	337	WO 04/089900	10/21/2004	PCT	C07D	209/52			
•	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
	C1	Pharmacology an	de Groat and Yoshimura, "Pharmacology of the Lower Urinary Tract", <i>Annual Review of</i> Pharmacology and Toxicology, 41:691-721 (2001)						
	C2	concentration of in reaction", Biochem	nhibitor whi <i>mical Pharr</i>	nship between the inhibition ich causes 50 per cent inh macology, <u>22</u> :3099-3108 (ibition (<i>1₅₀₎</i> 1973)	of an enz	ymatic		
(СЗ	Birdsall et al., "Mu Sciences, 22(5):2		ceptors: it's a knockout", 7 01)	rends in F	Pharmacolo	ogical		
(C4	Brighty et al., "Sy Achiral Diamine",		1α,5α,6α)-6-Amino-3-azab 97-1099 (1996)	oicyclo[3.1	.0]hexane,	a Novel		
(C5	System", Synlett,	1100-1102		•	• •	J		
(C6	Chapple, "Muscar Urology, 55(Supp		or antagonists in the treatr 6 (2000)	nent of ove	eractive bl	adder",		
(C7		Eglen et al., "Muscarinic receptor ligands and their theraputic potential", Current Opinion in Chemical Biology, 3:426-432 (1999)						
(C8	Eglen et al., "Theraputic opportunities from muscarinic receptor research", <i>Trends in Pharmacological Sciences</i> , <u>22</u> (8):409-414 (2001)							
C	C9		Felder et al., "Theraputic Opportunities for Muscarinic Receptors in the Central Nervous System", <i>Journal of Medicinal Chemistry</i> , 43(23):4333-4353 (2000)						
C	210	Grover et al., "Ch	iral Mandel	ic Acid Template Provides nal of Organic Chemistry,	a Highly F	Practical S			
C	211	Shacklett and Sm	ith, "The Pr	reparation of Substituted E . <u>75</u> :2654-2657 (1953)					
С	12	Sagara et al., "Cy	clohexylme criminating	thylpiperidinyltriphenylpro against the Other Recept					
С	13	Nkpa and Chedek	el, "Mecha	nistic Studies on the Addit urnal of Organic Chemistr	tion of Cys y, 46:213-2	teine to 3, 215 (1981)	4-		
С	14	Kadin and Canno	n, "Esters c	of N-Methyl-3-hydroxypipe nic Chemistry, <u>27</u> :240-245	ridine Hav	ing Psycho	otomimetic		
С	15	Broadley and Kell 193 (2001)	y, "Muscari	nic Receptor Agonists and	Antagoni	sts", <i>Molec</i>	cules, <u>6</u> :142-		

EXAMINER	/Susannah Chung/ (07/29/2008)	DATE CONSIDERED
*EXAMINER: Initia	al if reference considered, whether or not citation is in confi	ormance with MPEP 609: Oraw line through citation if not in conformance and not

considered. Include copy of this form with next communication to applicant.

Form PTO-1449

Receipt date: 01/19/2006 INFORMATION DISCLOSURE CITATION	Docket No.: RLL-256.1CIPUS	10520572 - GAU: 1626 Serial No.: 10/520,572
	Applicants: MEHTA et al.	
	Filed: 1/7/2005	Group:

	·
C16	Moriya et al., "Affinity Profiles of Various Muscarinic Antagonists for Cloned Human Muscarinic Acetylcholine Receptor (mAChR) Subtypes and mAChRs in Rat Heart and Submandibular Gland", <i>Life Sciences</i> , 64(25):2351-2358 (1999)
C17	Kubo et al., "Cloning, sequencing and expression of complementary DNA encoding the muscarinic acetylcholine receptor", <i>Nature</i> , 323(2):411-416 (1986)
C18	Bonner et al., "Identification of a Family of Muscarinic Acetylcholine Receptor Genes", Science, 237:527-531 (1987)
C19	Steers, "The future direction of neuro-urology drug research", Current Opinion in CPNS Investigational Drugs, 2(3):268-282
C20	Steers, Barrot, Wein, "Voiding dysfunction: diagnosis classification and management", In: <i>Adult and Pediatric Urology,</i> ed. Gillenwater, Grayhack, Howards, Duckett. Mosby, St. Louis, MO; 1220-1325, 3rd edition (1996)
C21	Weinstock et al., "A General, One-Step Synthesis of α -keto Esters", Synthetic Communications, 11(12):943-946 (1981)
C22	Vogel's textbook, "Practical Organic Chemistry" 1046-1047 (5th Ed.)
C23	"Design of prodrugs", ed. H. Bundgaard, Elsevier (1985)

EXAMINER	/Susannah Chung/ (07/29/2008)	DATE CONSIDERED	
			-

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.